The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LGVN | -61.71% | N/A | N/A | -99% |
| S&P | +16.23% | +94.45% | +14.22% | +71% |
Longeveron, Inc. is a clinical stage biotechnology company. It engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers on October 9, 2014 and is headquartered in Miami, FL.
Investors are reacting positively to the beginning of an Alzheimer's disease trial with Longeveron's lead candidate, Lomadel-B.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.32M | -32.5% |
| Gross Profit | -$0.12M | -201.7% |
| Gross Margin | -37.03% | -61.6% |
| Market Cap | $19.51M | 90.9% |
| Market Cap / Employee | $0.75M | 0.0% |
| Employees | 26 | 4.0% |
| Net Income | -$5.03M | -47.3% |
| EBITDA | -$5.13M | -57.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $10.33M | -16.5% |
| Accounts Receivable | $0.03M | -85.8% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.50M | -56.1% |
| Short Term Debt | $0.64M | 5.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -102.59% | -0.9% |
| Return On Invested Capital | -104.61% | -6.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.76M | 21.1% |
| Operating Free Cash Flow | -$3.60M | 21.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.25 | 1.00 | 1.05 | 1.13 | -15.00% |
| Price to Sales | 14.28 | 10.77 | 10.42 | 9.41 | 10.40% |
| Price to Tangible Book Value | 1.48 | 1.10 | 1.18 | 1.31 | -74.90% |
| Enterprise Value to EBITDA | -1.19 | -1.98 | -2.13 | -2.01 | -4602.26% |
| Return on Equity | -110.7% | -111.2% | -167.6% | -134.5% | -5.03% |
| Total Debt | $1.60M | $1.45M | $1.30M | $1.14M | -34.78% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
